Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 10
1981 20
1982 12
1983 14
1984 37
1985 43
1986 46
1987 46
1988 66
1989 62
1990 48
1991 59
1992 82
1993 90
1994 67
1995 56
1996 64
1997 48
1998 68
1999 53
2000 55
2001 68
2002 58
2003 57
2004 53
2005 59
2006 61
2007 46
2008 73
2009 71
2010 65
2011 66
2012 80
2013 63
2014 78
2015 97
2016 71
2017 57
2018 66
2019 63
2020 69
2021 64
2022 49
2023 45
2024 58
2025 63
2026 30

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,461 results

Results by year

Filters applied: . Clear all
Page 1
Triptorelin for the treatment of endometriosis.
Leone Roberti Maggiore U, Scala C, Remorgida V, Venturini PL, Del Deo F, Torella M, Colacurci N, Salvatore S, Ferrari S, Papaleo E, Candiani M, Ferrero S. Leone Roberti Maggiore U, et al. Expert Opin Pharmacother. 2014 Jun;15(8):1153-79. doi: 10.1517/14656566.2014.916279. Expert Opin Pharmacother. 2014. PMID: 24832495 Review.
INTRODUCTION: Over the past 30 years, gonadotropin-releasing hormone agonists (GnRH-a) have been used to induce a hypoestrogenic status in women with endometriosis with the aim to cause an improvement in pain symptoms similar to that observed after menopause. Triptorelin i …
INTRODUCTION: Over the past 30 years, gonadotropin-releasing hormone agonists (GnRH-a) have been used to induce a hypoestrogenic status in w …
Triptorelin embonate (6-month formulation).
Keating GM. Keating GM. Drugs. 2010 Feb 12;70(3):347-53. doi: 10.2165/11202230-000000000-00000. Drugs. 2010. PMID: 20166771 Review.
A 6-month formulation of the gonadotropin-releasing hormone agonist triptorelin embonate (designed to deliver 22.5 mg of triptorelin over a 6-month period) has been developed for use in the treatment of advanced prostate cancer. ...Drug-related adverse events (e.g. …
A 6-month formulation of the gonadotropin-releasing hormone agonist triptorelin embonate (designed to deliver 22.5 mg of triptorel …
Triptorelin depot for the treatment of children 2 years and older with central precocious puberty.
Bertelloni S, Mucaria C, Baroncelli GI, Peroni D. Bertelloni S, et al. Expert Rev Clin Pharmacol. 2018 Jul;11(7):659-667. doi: 10.1080/17512433.2018.1494569. Epub 2018 Jul 26. Expert Rev Clin Pharmacol. 2018. PMID: 29957076 Review.
Triptorelin depot is largely used to treat central precocious puberty (CPP) in children. Areas covered: This review updates triptorelin depot treatment of CPP, focusing on trials that compared 3.75 mg/28 day treated and untreated children till the adult height (AH). …
Triptorelin depot is largely used to treat central precocious puberty (CPP) in children. Areas covered: This review updates tripto …
Triptorelin in the management of prostate cancer.
Ploussard G, Mongiat-Artus P. Ploussard G, et al. Future Oncol. 2013 Jan;9(1):93-102. doi: 10.2217/fon.12.158. Future Oncol. 2013. PMID: 23252566 Review.
To illustrate the role of medical castration in prostate cancer, this paper reviews data on the GnRH agonist triptorelin long-duration and shorter-duration formulations. A similar proportion of patients achieved and maintained castration levels of serum testosterone ( 50 n …
To illustrate the role of medical castration in prostate cancer, this paper reviews data on the GnRH agonist triptorelin long-duratio …
Triptorelin: A Review of its Use as an Adjuvant Anticancer Therapy in Early Breast Cancer.
Frampton JE. Frampton JE. Drugs. 2017 Dec;77(18):2037-2048. doi: 10.1007/s40265-017-0849-3. Drugs. 2017. PMID: 29177573 Review.
A 1-month formulation of the gonadotrophin-releasing hormone agonist (GnRHa) triptorelin (Decapeptyl( )) has been approved in the EU as an adjuvant treatment in combination with tamoxifen or an aromatase inhibitor (AI), of endocrine-responsive, early-stage breast cancer in …
A 1-month formulation of the gonadotrophin-releasing hormone agonist (GnRHa) triptorelin (Decapeptyl( )) has been approved in the EU …
Triptorelin nanoparticle-loaded microneedles for use in assisted reproductive technology.
Lu X, Sun Y, Han M, Chen D, He X, Wang S, Sun K. Lu X, et al. Drug Deliv. 2023 Dec;30(1):2226367. doi: 10.1080/10717544.2023.2226367. Drug Deliv. 2023. PMID: 37387211 Free PMC article.
Triptorelin is a first-line drug for assisted reproductive technology (ART), but the low bioavailability and frequent subcutaneous injection of triptorelin impair the quality of life of women preparing to become pregnant. ...Triptorelin was mixed into an aque …
Triptorelin is a first-line drug for assisted reproductive technology (ART), but the low bioavailability and frequent subcutaneous in …
Triptorelin: The Need for Legal Protection Aimed at the Full Political and Social Integration of Gender Variant youth. A Comparison of Different Global realities.
Lacasella G, Volonnino G, Salducci M, Ottavian M, Spadazzi F, Karaboue MAA, Treglia M, Di Fazio N. Lacasella G, et al. Clin Ter. 2025 Nov-Dec;176(6):833-838. doi: 10.7417/CT.2025.5306. Clin Ter. 2025. PMID: 41267605 Free article. Review.
BACKGROUND: Triptorelin, a GnRH analogue, is used as a puberty blocker for transgender and gender-diverse adolescents experiencing gender dysphoria (GD). ...The study reviews both the advantages and the controversies surrounding GnRHa treatments, particularly for minors. F …
BACKGROUND: Triptorelin, a GnRH analogue, is used as a puberty blocker for transgender and gender-diverse adolescents experiencing ge …
[Pharmacokinetics and pharmacodynamics of triptorelin].
Lahlou N. Lahlou N. Ann Urol (Paris). 2005 Oct;39 Suppl 3:S78-84. doi: 10.1016/s0003-4401(05)80013-0. Ann Urol (Paris). 2005. PMID: 16302716 Review. French.
Pharmaceutical research has led to the development of delayed-release formulations allowing doses to be spaced by intervals of several weeks, or even three months when needed in some indications (Decapeptyl slow release). Triptorelin, as the other GnRH agonists, strongly r …
Pharmaceutical research has led to the development of delayed-release formulations allowing doses to be spaced by intervals of several weeks …
Triptorelin acetate administration in early pregnancy: case reports and review of the literature.
Chardonnens D, Sylvan K, Walker D, Bischof P, Sakkas D, Campana A. Chardonnens D, et al. Eur J Obstet Gynecol Reprod Biol. 1998 Oct;80(2):143-9. doi: 10.1016/s0301-2115(98)00109-2. Eur J Obstet Gynecol Reprod Biol. 1998. PMID: 9846657 Review.
We report 4 pregnancies occurring during pituitary downregulation with Triptorelin acetate in 366 in-vitro fertilization (IVF) cycles resulting in 3 deliveries of 4 normal neonates at term and 1 first trimester abortion. ...
We report 4 pregnancies occurring during pituitary downregulation with Triptorelin acetate in 366 in-vitro fertilization (IVF) cycles …
2,461 results